Doing less on purpose: fixed-duration regimens tested against treatment until progression, risk-adapted observation, and the evidence needed before an established therapy can safely be shortened or withheld.
RT CHARM (Alliance A221505) randomized 898 patients to conventional postmastectomy radiation (50 Gy in 25 fractions) or hypofractionated radiation (42.56 Gy in 16 fractions) after mastectomy with planned or completed breast reconstruction. Among 825 evaluable patients, the 24-month reconstruction complication rate was 12.3% with hypofractionation vs 10.2% with conventional radiation (difference −2.1%, 95% CI −6.5% to 2.2%), meeting the prespecified 10% non-inferiority margin (p = 0.0001).
EA1181 (CompassHER2 pCR) is a single-arm trial of de-escalated neoadjuvant therapy in Stage II–IIIa HER2-positive breast cancer: 12 weeks of a single taxane (paclitaxel, docetaxel or nab-paclitaxel) plus trastuzumab and pertuzumab (THP). In this secondary analysis of 2,141 evaluable patients, the overall pathologic complete response (pCR) rate was 43.8% (95% CI, 41.6%–45.9%).
A prespecified biomarker analysis of the phase 3 RxPONDER (SWOG S1007) trial finds that serum anti-Müllerian hormone (AMH), a marker of ovarian reserve, identifies which women under 55 with hormone receptor-positive, HER2-negative, node-positive breast cancer actually benefit from adding chemotherapy to endocrine therapy — outperforming menopausal status and age as a predictor.
Updated results from the prospective, single-arm POSITIVE trial — now with a median follow-up of 71 months, up from 41 months at the original analysis — found no increase in breast cancer recurrence risk among young women with hormone receptor-positive disease who paused adjuvant endocrine therapy to attempt pregnancy.
A nationwide Danish registry study of 8,134 patients found that age- and sex-standardized meningioma incidence nearly doubled between 2010 and 2023, rising from 6.4 to 12.6 cases per 100,000 person-years, while the proportion of diagnosed patients who ultimately received surgery fell from 43.9% to 23.4%.
A registry-based analysis of 11,681 US interventional cancer trials registered on ClinicalTrials.gov between 2008 and 2024 found that industry sponsors now outnumber federal sponsors nearly 5 to 1 (4.53-to-1 overall), with the ratio widening from 2.72-to-1 in 2008–2012 to 6.44-to-1 in 2019–2024.
Long-term follow-up (median exceeding 10 years) of NRG Oncology RTOG 0539 validates a risk-adapted meningioma strategy: observation after gross total or subtotal resection for low-risk (WHO grade 1) disease, and radiotherapy for intermediate- and high-risk disease.
Randomized phase 3 comparison, from the maintenance ("R2") randomization of the ECOG-ACRIN ENDURANCE (E1A11) trial, of indefinite-duration versus fixed 2-year lenalidomide maintenance in 516 standard-risk multiple myeloma patients who did not undergo up-front autologous stem-cell transplantation.
Phase 3 randomized trial of 909 patients with previously untreated CLL across 174 sites in 13 countries